+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating treatments for prostate cancer patients who have experienced a return of cancer markers biochemical recurrence after prostate surgery. This phase III trial compares whether adding enhanced therapy apalutamide with abiraterone and prednisone to standard care radiation therapy and short-term hormone therapy improves outcomes for patients without signs of cancer spread outside the pelvis. For patients with evidence of cancer spread beyond the pelvis detected by PET imaging, the study also tests whether adding targeted radiation to enhanced therapy provides additional benefit. Participants undergo baseline PET scans to identify the presence or absence of cancer spread outside the pelvis. Based on these results, they are randomly assigned to one of four treatment groups involving combinations of standard external radiation therapy, androgen deprivation therapies such as goserelin, leuprolide, triptorelin, relugolix, or degarelix, apalutamide taken daily by mouth, and for some, additional targeted radiation to metastatic sites. Treatments generally continue for six months unless disease progression or side effects occur. Patients may undergo additional PET imaging during the study to monitor response. Throughout the trial, participants will have regular follow-up visits every three months for two years, then every six months for years three to five, and annually up to ten years. Assessments include imaging scans, blood tests for prostate-specific antigen PSA, and quality-of-life evaluations using standardized questionnaires focusing on fatigue, pain, and cognitive function. Researchers will measure progression-free survival, overall survival, incidence of side effects, and quality of life up to ten years after treatment begins.

Age: 18Years +MALEPhase 3
341 locations